ReviewImmunological reviews2014
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
Review in Immunological reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 124 citations in OpenAlex.
- Engineered artificial antigen-presenting cells for tumor immunotherapy: Design strategies, clinical applications, and translational challenges.Materials today. Bio · 2026Review
- Antigen-boosted CD4CAR T cells fail to expand or control viremia in multiple nonhuman primate models of HIV.Blood · 2026Article
- Establishment of a serum-free culture system with an optimized 5-interleukin cytokine cocktail and insulin to promote preferential CD8⁺ T-cell expansion.Bioprocess and biosystems engineering · 2026Article
- Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting.Molecular oncology · 2026Article
- Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells.Antibody therapeutics · 2025Article
- Article
- MHC class I trafficking signal improves induction of cytotoxic T lymphocyte using artificial antigen presenting cells.Biochemistry and biophysics reports · 2025Article
- Occlusion of TCR binding to HLA-A*11:01 by a non-pathogenic human alloantibody.Cellular and molecular life sciences : CMLS · 2025Article
- Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC.Cancer gene therapy · 2025Article
- A synthetic cytotoxic T cell platform for rapidly prototyping TCR function.NPJ precision oncology · 2024Article
- Natural killer cell-related anti-tumour adoptive cell immunotherapy.Journal of cellular and molecular medicine · 2024Review
- A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function.bioRxiv : the preprint server for biology · 2023Article
- The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.Molecular cancer · 2023Review
- Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes.Science advances · 2023Article
- Biomimetic and bioinspired nano-platforms for cancer vaccine development.Exploration (Beijing, China) · 2023Review
- Article
- CAR-T: What Is Next?Cancers · 2023Review
- Strategies for enhancing CAR T cell expansion and persistence in HIV infection.Frontiers in immunology · 2023Review
- An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.Journal of nanobiotechnology · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Adoptive T-cell therapy, where anti-tumor T cells are first prepared in vitro, is attractive since it facilitates the delivery of essential signals to selected subsets of anti-tumor T cells without unfavorable immunoregulatory issues that exist in tumor-bearing hosts. Recent clinical trials have demonstrated that anti-tumor adoptive T-cell therapy, i.e. infusion of tumor-specific T cells, can induce clinically relevant and sustained responses in patients with advanced cancer. The goal of adoptive cell therapy is to establish anti-tumor immunologic memory, which can result in life-long rejection of tumor cells in patients. To achieve this goal, during the process of in vitro expansion, T-cell grafts used in adoptive T-cell therapy must be appropriately educated and equipped with the capacity to accomplish multiple, essential tasks. Adoptively transferred T cells must be endowed, prior to infusion, with the ability to efficiently engraft, expand, persist, and traffic to tumor in vivo. As a strategy to consistently generate T-cell grafts with these capabilities, artificial antigen-presenting cells have been developed to deliver the proper signals necessary to T cells to enable optimal adoptive cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.